Biogen Inc
NASDAQ: BIIB
$164.89
-$0.90 (-0.5%)
Closing Price on November 14, 2024
BIIB Articles
Canaccord Genuity recently released a report detailing some of the biggest biotech catalysts coming out over these next six months.
Published:
The May 29 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Tuesday's top analyst upgrades and downgrades included Avaya, Biogen, Broadcom, Chevron, Domino's Pizza, eBay, MGIC Investment, RealReal, Sprout Social, T-Mobile, Zoom Video Communications and Zynga.
Published:
Last Updated:
The May 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks was mixed.
Published:
The April 30 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
The April 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Thursday's top analyst upgrades and downgrades included Apple, AT&T, Avis Budget, Baidu, Baker Hughes, Biogen, Chipotle Mexican Grill, Kinder Morgan, Netflix, Shopify and Ulta Beauty.
Published:
Biogen reported better than expected first-quarter financial results before the markets opened on Wednesday.
Published:
24/7 Wall St. has put together a preview of a few of the most anticipated quarterly reports due this week, including Amazon, Tesla, Netflix and Starbucks.
Published:
The March 31 short interest data has been compared with the previous report, and short interest in these selected biotech stocks shrank.
Published:
The March 13 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
The February 28 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Many of the larger biotechnology and pharmaceutical companies have changed strategies from making acquisitions of speculative biotech outfits. In many cases it is far cheaper to just partner up with...
Published:
Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Biogen, Cree, Etsy, Gilead Sciences, Pfizer, Rite Aid, Solar Edge, Square, 3D Systems and Virgin Galactic.
Published:
The February 14 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published: